Nanobiotix reports 51M shares outstanding at Sept. 30

Nanobiotix S.A. reported 50,967,610 shares outstanding as of September 30, 2026, alongside 54,729,543 total theoretical voting rights and 54,707,425 total exercisable voting rights.

Rhea-AI Filing Summary

Nanobiotix S.A. reported 50,967,610 shares outstanding as of September 30, 2026, alongside 54,729,543 total theoretical voting rights and 54,707,425 total exercisable voting rights. The theoretical figure includes shares with voting rights suspended; the exercisable figure excludes shares held in treasury whose voting rights are suspended.

Key Figures

Shares outstanding: 50,967,610 shares Total theoretical voting rights: 54,729,543 voting rights Total exercisable voting rights: 54,707,425 voting rights

3 metrics

Shares outstanding 50,967,610 shares As of September 30, 2026

Total theoretical voting rights 54,729,543 voting rights As of September 30, 2026

Total exercisable voting rights 54,707,425 voting rights As of September 30, 2026

Key Terms

theoretical voting rights, exercisable voting rights, threshold crossings, shares held in treasury

4 terms

theoretical voting rights regulatory

"Total voting rights, theoretical"

Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.

exercisable voting rights regulatory

"Total voting rights, exercisable"

Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.

threshold crossings regulatory

"basis for calculating threshold crossings"

shares held in treasury financial

"shares held in treasury by the Company"

Shares held in treasury are stock a company issued and later repurchased, keeping those shares in its own ‘storage’ where they typically don’t vote or receive dividends. For investors this matters because treasury shares reduce the number of shares held by the public—potentially lifting per‑share earnings and changing ownership percentages—and the company can later reissue or retire them, which affects supply and possible dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and voting rights did Nanobiotix (NBTX) report?

As of September 30, 2026, Nanobiotix reported 50,967,610 shares outstanding, 54,729,543 total theoretical voting rights, and 54,707,425 total exercisable voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:15 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:15 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On October 20, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: October 20, 2026		/s/ Brandon Owens
		Brandon Owens
		Vice President, Strategic Marketing and Corporate Communications

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
September 30, 2026	50,967,610	54,729,543	54,707,425

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

_________________________________

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• 20261005-Nanobiotix-PR_Voting_Rights_sept_2026 (https://ml.globenewswire.com/Resource/Download/45333cef-a3b3-4e89-982b-34624efbfe43)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.7 KB